178 Effect of Dupilumab on Global Individual Signs Score Outcomes in Adults With Moderate-to-Severe Atopic Dermatitis: Combined Results From Four Phase 3 Trials

In phase 3 dupilumab (DPL) trials, the overall severity of 4 signs of atopic dermatitis (AD), erythema, infiltration/papulation, excoriation lichenification, was assessed globally through the investigator-assessed Global Individual Signs Score (GISS; range 0 –12). The effects of DPL on AD signs as measured by GISS in phase 3 trials are reported (LIBERTY AD: SOLO 1&2 [pooled] - NCT02277743/NCT02277769; CAF É - NCT02755649; CHRONOS - NCT02260986). Patients received subcutaneous DPL 300mg every 2 weeks (q2w) or placebo for 16 weeks (SOLO); DPL q2w + concomitant topical corticosteroids (TCS) or placebo + TCS for 16 weeks (CAFÉ); or 52 weeks (CHRONOS).

Source: Journal of Investigative Dermatology - August 31, 2019 Category: Dermatology Authors: P. Staubach-Renz, J. Silverberg, M. de Bruin-Weller, A.D. Irvine, M. Ardeleanu, Z. Chen, C. Clibborn, A. Sorrentino, A.B. Rossi Tags: Clinical Research and Epidemiology Source Type: research